Opening book details…
Can I read Plasma central carbon metabolite changes associated with KRAS mutation and circulating tumor DNA (ctDNA) status in colorectal cancer (CRC). on EtoBox?
Plasma central carbon metabolite changes associated with KRAS mutation and circulating tumor DNA (ctDNA) status in colorectal cancer (CRC). by Daniel Myung Kim; Francesca Paola Aguirre; Alexandra Gangi; Rocio Alvarez; Lisa Zhou; Johanna ten Hoeve; Yi Jou Liao; Thomas Graeber; Andrew Eugene Hendifar; Arsen Osipov; Kamya Sankar; May Thet Cho; Anser Abbas; John Davelaar; Megan Philippa Hitchins; Jun Gong is a Medicine article available to read on EtoBox.
What is Plasma central carbon metabolite changes associated with KRAS mutation and circulating tumor DNA (ctDNA) status in colorectal cancer (CRC). about?
181 Background: KRAS mutations have been widely characterized as markers of poor prognosis in CRC. In stage IV CRC, KRAS mutations are predictive of benefit to anti-EGFR therapy. ctDNA has increasingly been recognized as a prognostic biomarker in CRC as well. We evaluated the association between plasma metabolites and KRAS mutation or ctDNA status in a longitudinal, observational cohort of patients with stage I-IV CRC. Methods: This was a retrospective analysis of prospectively collected blood samples from a single-institute cohort of patients with stage I-IV CRC. All blood samples were collected at pre-chemotherapy baseline. A modified Epi proColon 2.0 CE (Epigenomics AG) assay was used for plasma ctDNA testing on the methylated SEPTIN9 gene (mSEPT9). ctDNA positivity was defined as a mSEPT9 percentage of methylation reference (PMR) value greater than zero. Up to 150 metabolites of central carbon metabolism were analyzed by mass spectrometry and high-performance liquid chromatography. Analytes were compared by relative area under the curve (AUC) and differences evaluated by ANOVA. The mean AUC was used in patients with metabolites measured from > 1 timepoint of collection. Patient
Who reads Plasma central carbon metabolite changes associated with KRAS mutation and circulating tumor DNA (ctDNA) status in colorectal cancer (CRC).?
It is typically read by researchers, students, and practitioners in Medicine.
- Author
- Daniel Myung Kim; Francesca Paola Aguirre; Alexandra Gangi; Rocio Alvarez; Lisa Zhou; Johanna ten Hoeve; Yi Jou Liao; Thomas Graeber; Andrew Eugene Hendifar; Arsen Osipov; Kamya Sankar; May Thet Cho; Anser Abbas; John Davelaar; Megan Philippa Hitchins; Jun Gong
- Publisher
- American Society of Clinical Oncology (ASCO)
- Published
- 2023
- Language
- EN
- Field
- Medicine (Health Sciences)